NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Lantheus Holdings, Inc. (LNTH) Stock Analysis

Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

LNTH

$100.97

−$0.01 (−0.01%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LNTH with… →

LNTH Key Statistics

As of Sep 4, 2026
Trading
Open
$100.75
Previous Close
$100.98
Day's Range
100.75–101.00
52-Week Range
49.67–111.86
Volume
859.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.03
Valuation
Market Cap
$6.59B
P/E Ratio
24.16
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.83
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.23
EPS (ttm)Profit attributable to each share over the last twelve months.
4.18
Financials (FY)
Revenue (FY)
$1.54B+0.50%
Net Income (FY)
$233.56M−25.25%
Profit marginThe share of revenue left as profit after all costs and taxes.
17.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.27M
1-Year Return
+87.61%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.34M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LNTH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+51.72%
2025−25.61%
2024+44.29%
2023+21.66%
2022+76.39%
2021+114.16%
2020−34.23%
2019+31.05%
2018−23.47%
2017+137.79%
2016 (partial year)+49.57%

As of September 4, 2026.

LNTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.54B$233.56M15.2%
2024$1.53B$312.44M20.4%
2023$1.30B$326.66M25.2%
2022$935.06M$28.07M3.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.54B$941.95M$315.56M$233.56M15.2%
2024$1.53B$988.29M$448.56M$312.44M20.4%
2023$1.30B$709.54M$364.64M$326.66M25.2%
2022$935.06M$581.70M$36.20M$28.07M3.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LNTH Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricLNTHDrug Manufacturers - Specialty & Generic medianvs median
P/E24.1619.2725% above
P/S ratio4.232.3084% above
Profit margin17.69%−3.14%20.8 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lantheus Holdings, Inc. (LNTH) carries a market capitalisation of $6.59B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 1,193.

LNTH last closed at $100.97 on September 4, 2026. That is −$0.01 (−0.01%) against the previous close. The 52-week range on file runs from $49.67 to $111.86. The latest close sits 103.28% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.54B. Against the prior fiscal year total of $1.53B, that is a change of +0.50%. Net income for the same year was $233.56M. That is −25.25% against the prior fiscal year. The reported profit margin is 17.69%. That is 20.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 4.18.

Across the 4 fiscal years on file, revenue moves from $935.06M in 2022 to $1.54B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

LNTH trades at a trailing price-to-earnings ratio of 24.16. That is 25.41% above the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 15.83. The price-to-sales ratio is 4.23. On price-to-sales that is 84.42% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +87.61%. Across 10 years the annualized return works out at +26.80%. The reported beta is −0.03. Annualized volatility over the trailing 10 years is 56.72%.

Growth & Income

No dividend is on file for LNTH.

The strongest complete calendar year on file is 2017 at +137.79%; the weakest is 2020 at −34.23%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the price is +51.72%.

Peer Comparison

Lantheus Holdings, Inc. (LNTH) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lantheus Holdings, Inc. LNTH $6.59B 24.2
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Lantheus Holdings, Inc. trades at a P/E of 24.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Visit website →